Mesoblast Limited reported Ryoncil net revenues of US$30.3 million for the quarter ended March 31, 2026, with the company’s flagship product approaching US$100 million in cumulative net revenues since its launch last year. More significantly, the company achieved net operating cash spend of just US$4.1 million for the quarter, a substantial improvement driven by US$34.6 million in receipts and disciplined expense management. This combination of accelerating product revenue and constrained operating costs marks a critical inflection point for the biotech company’s path toward cash flow sustainability.
The company’s cash position of US$122 million at quarter-end provides a solid runway as Mesoblast navigates the remainder of its development pipeline. The improved operating cash spend is particularly noteworthy given that the company continues to invest in clinical trials, R&D initiatives, and commercial infrastructure. If Mesoblast can maintain this level of quarterly cash consumption while Ryoncil revenues continue to grow, the company could approach cash flow breakeven within a reasonable timeframe. For investors, this represents a shift from viewing the company primarily through the lens of cash burn to evaluating it as a commercial entity with meaningful revenue generation capability.
On the clinical front, Mesoblast achieved the patient recruitment target for its pivotal Phase 3 trial evaluating rexlemestrocel-L for chronic low back pain, a significant milestone that moves the company one step closer to potential approval of its second-generation product. Additionally, the FDA granted Investigational New Drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, which affects approximately 15,000 children in the United States. The company also received FDA clearance to initiate a label extension trial for Ryoncil in steroid-resistant acute graft-versus-host disease. These regulatory approvals represent near-term catalysts that could drive additional revenue streams and broaden Mesoblast’s addressable market.
During an R&D day held on April 8th in New York, Mesoblast unveiled its acquisition of an exclusive worldwide license to a chimeric antigen receptor technology platform designed to enhance the potency of mesenchymal stromal cell products. The company plans to apply this CAR technology to develop enhanced therapeutic candidates for conditions including ulcerative colitis, Crohn’s disease, and lupus nephritis. This acquisition represents a strategic effort to maintain innovation leadership in cell therapy and position the company for potential blockbuster opportunities in inflammatory diseases where current treatment options remain inadequate.
Investors should monitor Ryoncil’s commercial trajectory in coming quarters to assess whether the product can sustain its growth trajectory while the company expands into label extension and new indications. The Phase 3 trial readout for rexlemestrocel-L and the early-stage results from the Duchenne muscular dystrophy trial will merit close attention. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
